Table 4.
Incidence rates of immune-mediated diarrhea and colitis in IBD and control cohorts
| Groups | Total N | Number of events at 6 months (rate %) | Number of events at 1 year (rate %) | ||||
| ICI diarrhea | ICI colitis | imDC | ICI diarrhea | ICI colitis | imDC | ||
| All patients | 180 | 6 (3.3%) | 12 (6.7%) | 18 (10%) | 7 (3.9%) | 14 (7.8%) | 21 (11.7%) |
| Control | 150 | 3 (2%) | 4 (2.7%) | 7 (4.7%) | 4 (2.7%) | 6 (4%) | 10 (6.7%) |
| IBD | 30 | 3 (10%) | 8 (26.7%) | 11 (36.7%) | 3 (10%) | 8 (26.7%) | 11 (36.7%) |
Event, ICI colitis or ICI diarrhea; IBD, inflammatory bowel disease; ICI, immune checkpoint inhibitor; imDC, immune-mediated diarrhea and colitis; N, total sample size.